Verici has raised gross £6.35m ($8.4m), net £5.8m ($7.7m), providing the growth capital required to accelerate its commercial plans. The fundraise extends cash runway to H2 26 and positions the company to capitalise on the recent award of Medicare Coverage for Tutivia. Importantly, Verci expects to deliver c. 1,450 Tutivia tests in FY25 (+334% vs FY24), which should accelerate even further in FY26 and beyond, as it fully benefits from the additional commercial investment. Verici also continues to invest in Protega and the urine platform, creating optionality for longer term value creation. We move to BUY with a TP of 2.9p.
